Duke Clinical Research Institute Durham NC.
Canadian VIGOUR Centre University of Alberta Edmonton Alberta Canada.
J Am Heart Assoc. 2020 Jul 7;9(13):e016033. doi: 10.1161/JAHA.120.016033. Epub 2020 Jun 17.
Background Despite restoration of epicardial flow following primary percutaneous coronary intervention (PPCI), microvascular reperfusion as reflected by ST-elevation resolution (ST-ER) resolution remains variable and its pathophysiology remains unclear. Methods and Results Using principal component analyses, we explored associations between 91 serum biomarkers drawn before PPCI clustered into 14 pathobiologic processes (including NT-proBNP [N-terminal pro-B-type natriuretic peptide] as an independent cluster), and (1) ST-ER resolution ≥50% versus <50%; and (2) 90-day composite of death, shock, and heart failure. Network analyses were performed to understand interbiomarker relationships between the ST-ER groups. Among the 1160 patients studied, 861 (74%) had ST-ER ≥50% at a median 40 (interquartile range, 23-70) minutes following PPCI, yet both groups had comparable post-PPCI TIMI (Thrombolysis in Myocardial Infarction) grade 3 flow (86.6% versus 82.9%; =0.25). ST-ER ≥50% was associated with significantly lower pre-PPCI concentrations of platelet activation cluster (particularly P-selectin, von Willebrand factor, and platelet-derived growth factor A) and NT-proBNP, including after risk adjustment. Across both ST-ER groups, strong interbiomarker relationships were noted between pathways indicative of myocardial stretch, platelet activation, and inflammation, whereas with ST-ER <50% correlations between iron homeostasis and inflammation were observed. Of all 14 biomarker clusters, only NT-proBNP was significantly associated with the 90-day clinical composite. Conclusions Suboptimal ST-ER is common despite achieving post-PPCI TIMI grade 3 flow. The cluster of platelet activation proteins and NT-proBNP were strongly correlated with suboptimal ST-ER and NT-proBNP was independently associated with 90-day outcomes. This analysis provides insights into the pathophysiology of microvascular reperfusion in ST-segment-elevation myocardial infarction and suggests novel pre-PPCI risk targets potentially amenable to enhancing tissue-level reperfusion following PPCI.
尽管经皮冠状动脉介入治疗(PPCI)后心外膜血流得到恢复,但微血管再灌注(以 ST 段抬高缓解程度(ST-ER)来反映)仍然存在差异,其病理生理学机制尚不清楚。
我们使用主成分分析方法,探索了 91 种在 PPCI 前采集的血清生物标志物,这些生物标志物聚类为 14 个病理生物学过程(包括作为独立聚类的 NT-proBNP[氨基末端 B 型利钠肽前体]),与(1)ST-ER 缓解程度≥50%与<50%;和(2)90 天死亡、休克和心力衰竭的复合结局之间的相关性。进行网络分析以了解 ST-ER 组之间生物标志物之间的相互关系。在研究的 1160 例患者中,861 例(74%)在 PPCI 后中位数 40 分钟(四分位距,23-70 分钟)时 ST-ER≥50%,但两组的 PPCI 后 TIMI(心肌梗死溶栓)分级 3 级血流(86.6%与 82.9%;=0.25)均相似。ST-ER≥50%与 PPCI 前血小板激活簇(尤其是 P-选择素、血管性血友病因子和血小板衍生生长因子 A)和 NT-proBNP 浓度显著降低相关,包括风险调整后也是如此。在两个 ST-ER 组中,心肌拉伸、血小板激活和炎症相关途径之间存在很强的生物标志物关系,而 ST-ER<50%时,铁稳态与炎症之间存在相关性。在所有 14 个生物标志物簇中,只有 NT-proBNP 与 90 天临床复合结局显著相关。
尽管 PPCI 后达到 TIMI 分级 3 级血流,但 ST-ER 不理想仍很常见。血小板激活蛋白簇和 NT-proBNP 与 ST-ER 不理想密切相关,NT-proBNP 是 90 天结局的独立预测因素。这项分析提供了 ST 段抬高型心肌梗死微血管再灌注病理生理学的见解,并提示了新型的 PPCI 前风险靶点,可能有助于增强 PPCI 后的组织水平再灌注。